TransCode Therapeutics financials
$1.63−4.68%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$6.8M | -$17.8M | -$16.0M | -$4.6M | -$4.2M | -$3.2M | -$5.1M | -$2.2M | -$5.1M | -$3.3M | -$4.1M | -$5.3M |
| Net income | -$6.9M | -$19.5M | -$15.1M | -$4.9M | -$4.3M | -$12.1M | -$5.9M | -$2.3M | -$5.2M | -$3.3M | -$4.1M | -$5.3M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-7.17 | $-21.28 | $-16.38 | $-5.82 | $-5.13 | $-70.16 | $-133.73 | $-146.06 | $-680.23 | $-597.80 | $-205.29 | $-44758.56 |
| EBITDA | -$6.8M | -$17.7M | -$7.2M | -$4.6M | -$4.2M | -$3.2M | -$5.1M | -$2.1M | -$5.1M | -$3.3M | -$4.1M | -$5.3M |
| Operating cash flow | -$5.4M | -$5.0M | -$8.1M | -$4.1M | -$4.2M | -$3.1M | -$3.1M | -$3.9M | -$2.3M | -$3.9M | -$5.8M | -$3.4M |
| Free cash flow | -$5.4M | -$5.0M | -$8.1M | -$4.1M | -$4.2M | -$3.1M | -$3.1M | -$3.9M | -$2.3M | -$3.9M | -$5.8M | -$3.4M |
| Diluted shares | 1.0M | 0.9M | 0.9M | 0.8M | 0.8M | 0.2M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.4M | $12.8M | $17.8M | $2.8M | $7.4M | $11.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $652.4K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $151.0M | $157.2M | $162.4M | $5.2M | $8.3M | $13.2M |
| Total liabilities | $12.7M | $12.6M | $10.5M | $3.8M | $2.1M | $2.9M |
| Shareholders' equity | -$27.7M | $1.3M | $10.3M | $1.4M | $6.1M | $10.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology